ArticleScientific reports2026
Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) has high rates of recurrence and progression, yet its molecular landscape across different ethnicities remains poorly defined. We assembled a meta-cohort of 202 Asian NMIBC transcriptomes and identified three novel molecular subtypes (AC0, AC1, AC2) using non-negative matrix factorization clustering. These subtypes, each associated with distinct biological pathways and clinical outcomes, were externally validated across 22 datasets. Subtype-specific biomarkers (RABL6, MYBL2, RAD54L, and FAM64A) were confirmed by immunohistochemistry in an independent Asian cohort (n = 210), enabling the development of a machine-learning-based risk stratification model. AC1, characterized by aggressive features and enrichment of cell cycle and oncogenic signaling pathways, exhibited the poorest prognosis. Notably, after adjustment for T-stage and grade, the combined risk model was independently prognostic in Asian cohorts but not in European cohorts, underscoring ethnic differences in NMIBC biology. Our findings delineate distinct molecular subtypes and introduce a clinically applicable, ethnicity-specific prognostic model for Asian patients with NMIBC. This study emphasizes the importance of incorporating ethnic diversity into precision oncology frameworks and provides a foundation for personalized therapeutic and surveillance strategies in underrepresented populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.